FierceBiotech 25. Nov. 2025 <a href="https://www.fiercebiotech.com/pharma/novos-shares-tumble-8-after-2-trial-misses-semaglutide-alzheimers-disease" hreflang="en">Novo shares tumble after 2 trial misses for semaglutide in Alzheimer's disease</a> #Alzheimer disease #Novo Nordisk
Endpoints News 24. Nov. 2025 Novo Nordisk's semaglutide misses in closely-watched Alzheimer’s trials #Novo Nordisk #closely-watched Alzheimer
BioWorld 24. Nov. 2025 Novo’s semaglutide fails in phase III Alzheimer’s trials #phase III #III Alzheimer
BioPharma Dive 24. Nov. 2025 Novo Nordisk’s GLP-1 misses goal in closely watched Alzheimer’s studies #Novo Nordisk #watched Alzheimer
Endpoints News 21. Nov. 2025 Novo, Lilly begin to sell obesity medications directly to employers #Novo Nordisk #Eli Lilly
Lonza News 7. Okt. 2025 Biotechnology Market Therapeutic Innovations & Forecast Report 2025-2033 Featuring Lonza, Amgen, Syngenta, Biocon, Biogen, F. Hoffmann-La Roche, Novartis, Novo Nordisk A/S, Pfizer, and Seagen - ResearchAndMarkets.com - Business Wire #Therapeutic Innovations #Forecast Report